SCHEMBL709840

SCHEMBL709840

COc1ccc(-c2cnc3[nH]c(-c4cc(OCc5ccccc5)ccc4OC(C)C)nc3c2)c(OC)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 4/20 0.42
GRIN2B Q13224 4/20 0.42
MAPT P10636 5/20 0.41
MAPK1 P28482 2/20 0.41
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
ALOX12 P18054 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KIT P10721 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
NOD2 Q9HC29 1/20 0.39
CYP2E1 P05181 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C8 P10632 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2B6 P20813 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713393 0.95 GRIN1 (0.43) GRIN1GRIN2BMAPTMAPK1PDGFRB
SCHEMBL712803 0.93 MAPT (0.44) MAPTMAPK1PDGFRBPDGFRAALDH1A1
SCHEMBL710136 0.91 MAPT (0.43) MAPTMAPK1PDGFRBPDGFRAKIT
SCHEMBL720491 0.90 MAPT (0.46) GRIN1GRIN2BMAPTMAPK1PDGFRB
SCHEMBL10206516 0.89 MCL1 (0.41) MAPTMAPK1PDGFRBPDGFRAALDH1A1
SCHEMBL708937 0.88 GRIN1 (0.42) GRIN1GRIN2BMAPTMAPK1PDGFRB
SCHEMBL720489 0.88 MAPT (0.46) MAPTMAPK1PDGFRBPDGFRANPSR1
SCHEMBL713544 0.87 FFAR1 (0.40) PDGFRBPDGFRAKITPRMT5TLR8
SCHEMBL712000 0.86 PRMT5 (0.38) MAPTMAPK1PDGFRBPDGFRAGAA
SCHEMBL10206529 0.86 MAPT (0.41) MAPTMAPK1PDGFRBPDGFRAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK GRIN1 1844/4885GRIN2B 1536/4885MAPT 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.